A Study of the Effects of Preterm Birth on Lung Disease and Innate Immunity Later in Life


About this study

The primary purpose of this study is to investigate the cytokine responses of blood ILC2s from preterm children by collecting peripheral blood at age 5-10 years from children born either preterm or at term, and to analyze the functions of their circulating ILC2s in vitro.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Children aged 5-10 years at the time of enrollment.
  • Those who receive medical care from Mayo Clinic.
  • Those born either:
    • preterm (< 37 weeks of gestation) who received supplemental oxygen within 2 weeks after birth with (n=12) and without asthma (n=12); or term (>= 37 weeks of gestation) without asthma (n=12).
  • Those with a weight of 17 kgs or greater.

Exclusion Criteria:

  • Those who have a history of chronic lung diseases such as cystic fibrosis, pulmonary fibrosis, lung cancer, or bronchopulmonary dysplasia.
  • Those who do not receive primary medical care from Mayo Clinic.  

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hirohito Kita, M.D.

Open for enrollment

Contact information:

Julie Porcher



More information


Publications are currently not available